Etiology, Epidemiology, and Natural History

Urologic Clinics of North America

Volumn 36, Issue 4, 2009, Pages 403-415

  Bushman, Wade ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Lower urinary tract symptoms; Metabolic risk factors; Prostatic enlargement

Indexed keywords

ACUTE DISEASE; AGING; DETRUSOR MUSCLE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; HISTOPATHOLOGY; HUMAN; INCIDENCE; LOWER URINARY TRACT SYMPTOM; METABOLIC SYNDROME X; PATHOGENESIS; PATHOPHYSIOLOGY; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; URINE RETENTION;

DISEASE PROGRESSION; HUMANS; INCIDENCE; INFLAMMATION; MALE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROSTATISM; RISK FACTORS;

EID: 70449724699     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2009.07.003     Document Type: Review

References (130)

1. Bierhoff E., Vogel J., Benz M., et al. Stromal nodules in benign prostatic hyperplasia. Eur Urol 29 (1996) 345-354
2. Meigs J.B., Mohr B., Barry M.J., et al. Risk factors for clinical benign prostatic enlargement in a community-based population of healthy aging men. J Clin Epidemiol 54 (2001) 935-944
3. Michel M.C., Mehlburger L., Schumacher H., et al. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. J Urol 163 6 (2001) 1725-1729
4. Verhamme K., Dieleman J., Bleumink G., et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic enlargement in primary care-the Triumph project. Eur Urol 42 (2002) 323-328
5. McNeal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am 17 3 (1990) 477-486
6. McNeal J.E. Origin and evolution of benign prostatic enlargement. Invest Urol 15 4 (1978) 340-345
7. Thomson A.A., and Marker P.C. Branching morphogenesis in the prostate gland and seminal vesicles. Differentiation 74 7 (2006) 382-392
8. Gooren L. Androgen deficiency in the aging male: benefits and risks of androgen supplementation. J Steroid Biochem Mol Biol 85 2-5 (2003) 349-355
9. Green J.S., Holden S.T., Bose P., et al. An investigation into the relationship between prostate size, peak urinary flow rate and male erectile dysfunction. Int J Impot Res 13 6 (2001) 322-325
10. Kaufman J.M. The effect of androgen supplementation therapy on the prostate. Aging Male 6 3 (2003) 166-174
11. Kirby R.S., Lowe D., and Bultitude M.I. Intra-prostatic urinary reflux: an aetiological factor in abacterial prostatitis. Br J Urol 54 6 (1982) 729-731
12. Marks L.S., Mostaghel E.A., and Nelson P.S. Prostate tissue androgens: history and current clinical relevance. Urology 72 2 (2008) 247-254
13. Masumori N., Tsukamoto T., Kumamoto Y., et al. Japanese men have smaller prostate volumes but comparable urinary flow rates relative to American men: results of community based studies in 2 countries. J Urol 155 4 (1996) 1324-1327
14. Mostaghel E.A., and Nelson P.S. Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab 22 2 (2008) 243-258
15. Belanger A., Candas B., Dupont A., et al. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab 79 4 (1994) 1086-1090
16. Coffey D.S., and Walsh P.C. Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am 17 3 (1990) 461-475
17. Collins G.N., Lee R.J., Russell E.B., et al. Ultrasonically determined patterns of enlargement in benign prostatic hyperplasia. Br J Urol 71 4 (1993) 451-456
18. Fingerhut B., and Veenema R.J. Histology and radioautography of induced benign enlargement of the mouse prostate. Invest Urol 4 2 (1966) 112-124
19. Ricke W.A., McPherson S.J., Bianco J.J., et al. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB J 22 5 (2008) 1512-1520
20. Ricke W.A., Ishii K., Ricke E.A., et al. Steroid hormones stimulate human prostate cancer progression and metastasis. Int J Cancer 118 9 (2006) 2123-2131
21. Streng T.K., Talo A., Andersson K.E., et al. A dose-dependent dual effect of oestrogen on voiding in the male mouse?. BJU Int 96 7 (2005) 1126-1130
22. Delongchamps N.B., de la Roza G., Chandan V., et al. Evaluation of prostatitis in autopsied prostates-is chronic inflammation more associated with benign prostatic hyperplasia or cancer?. J Urol 179 (2008) 1736-1740
23. de la Rosette J.J., Witjes W.P., Schäfer W., et al. Relationships between lower urinary tract symptoms and bladder outlet obstruction: results from the ICS-"BPH" study. Neurourol Urodyn 17 2 (1998) 99-108
24. Kohnen P.W., and Drach G.W. Patterns of inflammation in prostatic hyperplasia: a histologic and bacterial study. J Urol 121 (1979) 755-760
25. Kramer G., and Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia?. Curr Opin Urol 16 (2006) 25-29
26. Steiner G., Gessl A., Kramer G., et al. Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia. J Urol 151 (1994) 480-484
27. Theyer G., Kramer G., and Assmann I. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 66 (1992) 96-107
28. McNeal J.E. Regional morphology and pathology of the prostate. Am J Clin Pathol 49 3 (1968) 347-357
29. Bennett B.D., Culberson D.E., and Petty C.S. Histopathology of prostatitis. [abstract]. J Urol 143 (1990) 265
30. Weiss J.P., Wein A., Jacobs J., et al. Use of nitrofurantoin macro-crystals after transurethral prostatectomy. J Urol 130 (1983) 479
31. De Marzo A.M., Platz E.A., Sutcliffe S., et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 7 (2007) 256-269
32. Nickel J.C., Downey J., Young I., et al. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 84 (1999) 976-981
33. Gerstenbluth R.E., Seftel A.D., MacLennan G.T., et al. Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation. J Urol 167 (2002) 2267-2270
34. Roehrborn C.G. Benign prostatic hyperplasia: an overview. Rev Urol 7 9 (2005) S3-S14
35. Roehrborn C.G. Definition of at-risk patients: baseline variables. BJU Int 97 Suppl 2 (2006) 7-11 [discussion: 21-2]
36. Nickel J.C., Roehrborn C.G., O'Leary M.P., et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 54 (2008) 1379-1384
37. Nickel J.C. Inflammation and benign prostatic hyperplasia. Urol Clin North Am 35 (2007) 109-115
38. Parsons J.K., Carter H.B., Partin A.W., et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 91 7 (2006) 2562-2568
39. Popp K.A. Assignment of patients into the classification of cardiomyopathies. Circulation 86 5 (1992) 1622-1633
40. Boon T.A., Van Venrooij G.E., and Eckhardt M.D. Effect of diabetes mellitus on lower urinary tract symptoms and dysfunction in patients with benign prostatic hyperplasia. Curr Urol Rep 2 4 (2001) 297-301
41. Bostwick D.G., Cooner W.H., Denis L., et al. The association of benign prostatic hyperplasia and cancer of the prostate. Cancer 70 Suppl 1 (1992) 291-301
42. Carson C., and Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61 4 Suppl 1 (2003) 2-7
43. Hammarsten J., and Högstedt B. Calculated fast-growing benign prostatic hyperplasia-a risk factor for developing clinical prostate cancer. Scand J Urol Nephrol 36 5 (2002) 330-338
44. Hammarsten J., and Högstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 39 2 (2001) 151-158
45. Hammarsten J., and Högstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 8 1 (1999) 29-36
46. Hedelin H., Johansson N., and Ströberg P. Relationship between benign prostatic hyperplasia and lower urinary tract symptoms and correlation between prostate volume and serum prostate-specific antigen in clinical routine. Scand J Urol Nephrol 39 2 (2005) 154-159
47. De Marzo A.M., Marchi V.L., Epstein J.I., et al. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 155 (1999) 1985-1992
48. Nelson W.G., De Marzo A.M., DeWeese T.L., et al. The role of inflammation in the pathogenesis of prostate cancer. J Urol 172 5 Pt 2 (2004) S6-S11
49. Nelson W.G., De Marzo A.M., and Isaacs W.B. Prostate cancer. N Engl J Med 349 4 (2003) 366-381
50. Nelson W.G., De Marzo A.M., and DeWeese T.L. The molecular pathogenesis of prostate cancer: Implications for prostate cancer prevention. Urology 57 (2001) 39-45
51. Köhler T.S., and McVary K.T. The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. Eur Urol (2008)
52. McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 97 Suppl 2 (2006) 23-28 [discussion: 44-5]
53. McVary K.T., Rademaker A., Lloyd G.L., et al. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 174 4 Pt 1 (2005) 1327-1433
54. Rosen R.C., Wei J.T., Althof S.E., et al. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry. Urology 73 3 (2009) 562-566
55. Clemens J.Q., Markossian T.W., Meenan R.T., et al. Overlap of voiding symptoms, storage symptoms and pain in men and women. J Urol 178 4 Pt 1 (2007) 1345-1348
56. Dubeau C.E. The aging lower urinary tract. J Urol 175 3 Pt 2 (2006) S11-S15
57. Dutkiewicz S., Witeska A., and Stepień K. Relationship between prostate-specific antigen, prostate volume, retention volume and age in benign prostatic hypertrophy (BPH). Int Urol Nephrol 27 6 (1995) 763-768
58. Elbadasi A., Diokno A.C., and Millard R.J. The aging bladder: morphology and urodynamics. World J Urol 16 Suppl 1 (1998) S10-S34
59. Nordling J. The aging bladder-a significant but underestimated role in the development of lower urinary tract symptoms. Exp Gerontol 37 8-9 (2002) 991-999
60. Ozayar A., Zumrutbas A.E., and Yaman O. The relationship between lower urinary tract symptoms (LUTS), diagnostic indicators of benign prostatic hyperplasia (BPH), and erectile dysfunction in patients with moderate to severely symptomatic BPH. Int Urol Nephrol 40 4 (2008) 933-939
61. Ozden C., Ozdal O.L., Urgancioglu G., et al. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 51 1 (2007) 199-203 discussion 204-6
62. Palapattu G.S., Sutcliffe S., Bastian P.J., et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 26 7 (2005) 1170-1181
63. Nandeesha H. Benign prostatic hyperplasia: dietary and metabolic risk factors. Int Urol Nephrol 40 (2008) 649-656
64. Guo L.J., Zhang X.H., Li P.J., et al. Association study between benign prostatic hyperplasia and primary hypertension. Zhonghua Wai Ke Za Zhi 43 2 (2005) 108-111
65. Steers W.D., Clemow D.B., Persson K., et al. Tuttle the spontaneously hypertensive rat: insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males. Exp Physiol 84 1 (1999) 137-147
66. Kasturi S., Russell S., and McVary K.T. Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep 7 4 (2006) 288-292
67. Geppetti P., Nassini R., Materazzi S., et al. The concept of neurogenic inflammation. BJU Int 101 Suppl 3 (2008) 2-6
68. Giovannucci E., Rimm E.B., Chute C.G., et al. Am Obesity and benign prostatic hyperplasia. J Epidemiol 140 11 (1994) 989-1002
69. Compérat E., Reitz A., Delcourt A., et al. Histologic features in the urinary bladder wall affected from neurogenic overactivity-a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol 50 (2006) 1058-1064
70. Marchand J.E., Sant G.R., and Kream R.M. Increased expression of substance P receptor- encoding mRNA in bladder biopsies from patients with interstitial cystitis. Br J Urol 81 (1998) 224-228
71. Nazif O., Teichman J.M., and Gebhart G.F. Neural upregulation in interstitial cystitis. Urology 69 Suppl (2007) 24-33
72. Pang X., Marchand J., Sant G.R., et al. Increased number of substance P positive nerve fibres in interstitial cystitis. Br J Urol 75 (1995) 744-750
73. Qin C., Malykhina A.P., Akbarali H.I., et al. Cross-organ sensitization of lumbosacral spinal neurons receiving urinary bladder input in rats with inflamed colon. Gastroenterology 129 (2005) 1967-1978
74. Rudick C.N., Chen M.C., Mongiu A.K., et al. Organ cross talk modulates pelvic pain. Am J Physiol Regul Integr Comp Physiol 293 (2007) R1191-R1198
75. Ustinova E.E., Gutkin D.W., and Pezzone M.A. Sensitization of pelvic nerve afferents and mast cell infiltration in the urinary bladder following chronic colonic irritation is mediated by neuropeptides. Am J Physiol Renal Physiol 292 (2007) F123-F130
76. Ustinova E.E., Fraser M.O., and Pezzone M.A. Colonic irritation in the rat sensitizes urinary bladder afferents to mechanical and chemical stimuli: an afferent origin of pelvic organ cross-sensitization. Am J Physiol Renal Physiol 290 (2006) F1478-F1487
77. Nickel J.C., and Saad F. The American Urological Association 2003 guideline on management of benign prostatic hyperplasia: a Canadian opinion. Can J Urol 11 2 (2004) 2186-2193
78. Nickel J.C. The overlapping lower urinary tract symptoms of benign prostatic hyperplasiz and prostatitis. Curr Opin Urol 16 (2006) 5-10
79. Brookes S.T., Donovan J.L., Peters T.J., et al. Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomized control trial. Br Med J 324 (2002) 1059-1061
80. Frankel S.J., Donovan J.L., Peters T.I., et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol 51 (1998) 677-685
81. Rosen R., Altwein J., Boyle P., et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44 (2003) 637-649
82. Nickel J.C., Elhilali M., Vallancien G., and ALF-ONE Study Group. Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH. BJU Int 95 (2005) 571-574
83. Rhodes T., Girman C.J., Jacobsen S.J., et al. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol 161 4 (1999) 1174-1179
84. Ganpule A.P., Desai M.R., Desai M.M., et al. Natural history of lower urinary tract symptoms: preliminary report from a community-based Indian study. BJU Int 94 3 (2004) 332-334
85. Bosch J.L., Kranse R., van Mastrigt R., et al. Reasons for the weak correlation between prostate volume and urethral resistance parameters in patients with prostatism. J Urol 153 3 Pt 1 (1995) 689-693
86. Roehrborn C.G. The epidemiology of acute urinary retention in benign prostatic hyperplasia. Rev Urol 3 4 (2001) 187-192
87. Girman C.J., Jacobsen S.J., Guess H.A., et al. Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol 153 5 (1995) 1510-1515
88. Bosch J.L., Hop W.C., Kirkels W.J., et al. The International Prostate Symptom Score in a community-based sample of men between 55 and 74 years of age: prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. Br J Urol 75 5 (1995) 622-630
89. Vesely S., Knutson T., Damber J.E., et al. Relationship between age, prostate volume, prostate-specific antigen, symptom score and uroflowmetry in men with lower urinary tract symptoms. Scand J Urol Nephrol 37 4 (2003) 322-328
90. Ezz el Din K., Kiemeney L.A., de Wildt M.J., et al. Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score. Urology 48 3 (1996) 393-397
91. Lee T., Seong D.H., Yoon S.M., et al. Prostate shape and symptom score in benign prostatic hyperplasia. Yonsei Med J 42 5 (2001) 532-538
92. Girman C.J., Panser L.A., Chute C.G., et al. Natural history of prostatism: urinary flow rates in a community-based study. J Urol 150 3 (1993) 887-892
93. Vulchanova A., Wang L., Li X., et al. Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neuropeptides, the P2X3 purinoceptor and IB4 binding sites. Eur J Neurosci 11 (1999) 946-958
94. Nitti V.W., Kim Y., and Combs A.J. Correlation of the AUA symptom index with urodynamics in patients with suspected benign prostatic hyperplasia. Neurourol Urodyn 13 5 (1994) 521-527 [discussion: 527-9]
95. Netto Júnior N.R., D'Ancona C.A., and de Lima M.L. Correlation between the International Prostatic Symptom Score and a pressure-flow study in the evaluation of symptomatic benign prostatic hyperplasia. J Urol 155 1 (1996) 200-202
96. Yalla S.V., Sullivan M.P., Lecamwasam H.S., et al. Correlation of American Urological Association symptom index with obstructive and nonobstructive prostatism. J Urol 153 3 Pt 1 (1995) 674-679 [discussion: 679-80]
97. Zlotta A.R., Teillac P., Raynaud J.P., et al. Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (permixon), tamsulosin or finasteride. Eur Urol 48 2 (2005) 269-276
98. Madersbacher S., Klingler H.C., Schatzl G., et al. Age related urodynamic changes in patients with benign prostatic hyperplasia. J Urol 156 5 (1996) 1662-1667
99. Svanborg A. Age-related changes in cardiac physiology. Drugs Aging 10 6 (1997) 463-472
100. Lakatta E.G., and Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part II: the aging heart in health: links to heart disease. Circulation 107 2 (2003) 346-354
101. Lewis J.F., and Maron B.J. Cardiovascular consequences of the aging process. Cardiovasc Clin 22 2 (1992) 25-34
102. Roffe C. Aging of the heart. Br J Biomed Sci 55 2 (1998) 136-148
103. Lakatta E.G. Similar myocardial effects of aging and hypertension. Eur Heart J 11 Suppl G (1990) 29-38
104. Susic D., and Frohlich E.D. Hypertension and the heart. Curr Hypertens Rep 2 6 (2000) 565-569
105. Varagic J., Susic D., and Frohlish E. Heart, aging, and hypertension. Curr Opin Cardiol 16 6 (2001) 336-341
106. Carson P. Pharmacologic treatment of congestive heart failure. Clin Cardiol 19 4 (1996) 271-277
107. Hollenberg S.M. Vasodilators in acute heart failure. Heart Fail Rev 12 2 (2007) 143-147
108. Elbadawi A., Hailemariam S., Yalla S.V., et al. Structural basis of geriatric voiding dysfunction. VI. Validation and update of diagnostic criteria in 71 detrusor biopsies. J Urol 157 5 (1997) 1802-1813
109. Jensen K.M., Bruskewitz R.C., and Madsen P.O. Urodynamic findings in elderly males without prostatic complaints. Urology 24 2 (1984) 211-213
110. Saito M., Ohmura M., and Kondo A. Effect of ageing on blood flow to the bladder and bladder function. Urol Int 62 2 (1999) 93-98
111. Schäfer W. Urodynamics in benign prostatic hyperplasia (BPH). Arch Ital Urol Androl 65 6 (1993) 599-613
112. Tse V., Wills E., Szonyi G., et al. The application of ultrastructural studies in the diagnosis of bladder dysfunction in a clinical setting. J Urol 163 2 (2000) 535-539
113. Tsukamoto T., Masumori N., Rahman M., et al. Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally. Int J Urol 14 4 (2007) 321-324 [discussion: 325]
114. Van Mastrigt R. Age dependence of urinary bladder contractility. Neurourol Urodyn 11 (1992) 315-317
115. DiSanto M., Stein R., Chang S., et al. Alteration in expression of myosin isoforms in detrusor smooth muscle following bladder outlet obstruction. Am J Physiol Cell Physiol 285 (2003) C1397-C1410
116. Di Silverio F., Gentile V., De Matteis A., et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 43 (2003) 164-175
117. Greenland J.E., and Brading A.F. The effect of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs. J Urol 165 1 (2001) 245-248
118. Greenland J.E., Hvistendahl J.J., Andersen H., et al. The effect of bladder outlet obstruction on tissue oxygen tension and blood flow in the pig bladder. Br J Urol 85 9 (2000) 1109-1114
119. Lu S.H., Chang L.S., Yang A.H., et al. Mitochondrial DNA deletion of the human detrusor after partia bladder outlet obstruction-correlation withurodynamic analysis. Urology 55 4 (2000) 603-607
120. Lu S.H., Wei Y.H., Chang L.S., et al. Morphological and morphometric analysis of human detrusor mitochondria with urodynamic correlation after partial bladder outlet obstruction. J Urol 163 1 (2000) 225-229
121. Luo J., Dunn T., Ewing C., et al. Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. Prostate 51 3 (2002) 189-200
122. Nevel-McGarvey C.A., Levin R.M., Haugaard N., et al. Mitochondrial involvement in bladder function and dysfunction. Mol Cell Biochem 194 (1999) 1-15
123. Blaivas J.G., Flisser A.J., and Tash J.A. Treatment of primary bladder neck obstruction in women with transurethral resection of the bladder neck. J Urol 171 3 (2004) 1172-1175
124. Boluyt M.O. Matrix gene expression and decompensated heart failure: the aged SHR model. Cardiovasc Res 46 2 (2000) 239-249
125. Lee A.J., Garraway W.M., Simpson R.J., et al. The natural history of untreated lower urinary tract symptoms in middle-aged and elderly men over a period of five years. Eur Urol 34 4 (1998) 325-332
126. Jacobsen S.J., Girman C.J., and Lieber M.M. Natural history of benign prostatic hyperplasia. Urology 58 6 Suppl 1 (2001) 5-16 [discussion: 16]
127. Thomas A.W., Cannon A., Bartlett E., et al. The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic follow-up of untreated bladder outlet obstruction. BJU Int 96 9 (2005) 1301-1306
128. Al-Hayek S., Thomas A., and Abrams P. Natural history of detrusor contractility-minimum ten-year urodynamic follow-up in men with bladder outlet obstruction and those with detrusor. Scand J Urol Nephrol Suppl 215 (2004) 101-108
129. Andersson K.E. Storage and voiding symptoms: pathophysiologic aspects. Urology 62 5 Suppl 2 (2003) 3-10
130. Antunes A.A., Srougi M., Dall'oglio M.F., et al. The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening. J Sex Med 5 7 (2008) 1702-1707